Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 2Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 1476Neoplasms 999Colorectal Neoplasms 830Carcinoma, Non-Small-Cell Lung 724Carcinoma, Hepatocellular 683Stomach Neoplasms 647Lung Neoplasms 584Prostatic Neoplasms 543Pancreatic Neoplasms 456Rectal Neoplasms 338Uterine Cervical Neoplasms 303Colonic Neoplasms 295Neoplasm Metastasis 292Ovarian Neoplasms 285Esophageal Neoplasms 279Recurrence 278Leukemia, Myeloid, Acute 253Head and Neck Neoplasms 241Multiple Myeloma 232Brain Neoplasms 204Polycystic Ovary Syndrome 200Nasopharyngeal Carcinoma 198Melanoma 198Precursor Cell Lymphoblastic Leukemia-Lymphoma 195Urinary Bladder Neoplasms 193Lymphoma 178Liver Neoplasms 178Endometrial Neoplasms 159Motor Activity 147Lymphoma, Large B-Cell, Diffuse 141

Interventions

anlotinib 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × OTHER × Overall Survival × Clear all
NCT05218629 2023-03-29

Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

Qingdao Central Hospital

Phase 2 Unknown
20 enrolled

Overall Survival

NCT04050787 2019-08-08

Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer

The First Hospital of Jilin University

Phase NA Unknown
100 enrolled

Overall Survival

Data powered by HemOnc (CC BY 4.0) Colophon âš¡